Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells

Human Gene Therapy

Volumn 8, Issue 11, 1997, Pages 1375-1384

  Hirano, Naoto ^a   Takahashi, Tsuyoshi ^a   Takahashi, Tokiharu ^a   Azuma, Miyuki ^b   Okumura, Ko ^b   Yazaki, Yoshio ^a   Yagita, Hideo ^b   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; GENE THERAPY; IMMUNOCOMPETENCE; IRRADIATION; LEUKEMIA; MOUSE; MYELOID LEUKEMIA; NONHUMAN; RADIATION CARCINOGENESIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANIMALIA;

EID: 0030792796     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.11-1375     Document Type: Article

References (47)

1. ALEXANDER, M.A., BENNICELLI, J., and GUERRY, D. (1989). Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J. Immunol. 142, 4070-4078.
2. AZUMA, M., ITO, D., YOGITA, H., OKUMURA, K., PHILLIPS, J.H., LANIER, L.L., and SOMOZA, C. (1993). B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76-79.
3. BASKAR, S., NABAVI, N., GLIMCHER, L.H., and OSTRAND-ROSENBERG, S. (1993a). Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14, 209-215.
4. BASKAR, S., OSTRAND-ROSENBERG, S., NABAVI, N., NADLER, L.M., FREEMAN, G.J., and GLIMCHER, L.H. (1993b). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690.
5. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
6. BLAZAR, B.R., TAYLOR, P.A., LINSLEY, P.S., and VALLERA, D.A. (1994). In vivo blockade of CD28/CTLA4: B7/B1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825.
7. BOON, T., DE, P.E., LURQUIN, D., VAN DEN EYNDE, B., VAN DER BRUGGEN, P, TRAVERSARI, C., AMAR, C.A., and VAN PEL, A. (1992). Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surveys 13, 23-37.
8. CAVALLO, F., MARTIN, F.A., BELLONE, M., HELTAI, S., GATTI, E., TORNAGHI, P., FRESCHI, M., FORNI, G., DELLABONA, P., and CASORATI, G. (1995). Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25, 1154-1162.
9. CHEN, L., ASHE, S., BRADY, W.A., HELLSTRUÖM, I., HELLSTRÖM, K.E., LEDBETTER, J.A., McGOWAN, P., and LINSLEY, P.S. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
10. CHEN, L., McGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTRÖM, I., and HELLSTRÖM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
11. COLOMBO, M.P., FERRARI, G., STOPPACCIARO, A., PARENZA, M., RODOLFO, M., MAVILIO, F., and PARMIANI, G. (1991). Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173, 889-897.
12. DAMLE, N.K., KLUSSMAN, K., and ARUFFO, A. (1992a). Intercellular adhesion molecule-2, a second counter-receptor for CD11a/CD18 (leukocyte function-associated antigen-1), provides a costimulatory signal for T-cell receptor-initiated activation of human T cells. J. Immunol. 148, 665-671.
13. + T lymphocytes. J. Immunol. 148, 1985-1992.
14. + T lymphocytes. J. Immunol. 151, 2368-2379.
15. DAMLE, N.K., KLUSSMAN, K., LEYTZE, G., MYRDAL, S., ARUFFO, A., LEDBETTER, J.A., and LINSLEY, P.S. (1994). Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J. Immunol. 152, 2686-2697.
16. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
17. DUNUSSI-JOANNOPOULOS, K., WEINSTEIN, H.J., NICKERSON, P.W., STROM, T.B., BURAKOFF, S.J., CROOP, J.M., and ARCECI, R.J. (1996). Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87, 2938-2946.
18. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
19. FREEMAN, G.J., FREEDMAN, A.S., SEGIL, J.M., LEE, G., WHITMAN, J.F., and NADLER, L.M. (1989). B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143, 2714-2722.
20. FREEMAN, G.J., GRIBBEN, J.B., BOUSSIOTIS, V.A., NG, J.W., RESTIVO, V.J., LOMBARD, L.A., GRAY, G.S., and NADLER, L.M. (1993). Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-911.
21. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
22. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
23. GREENBERG, P.D. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281.
24. HELLSTRÖM, K.E., and HELLSTRÖM, I. (1993). Tumor immunology: An overview. Ann. N.Y. Adac. Sci. 690, 24-33.
25. HEUER, J.G., TUCKER-McCLUNG, C., GONIN, R., and HOCK, R.A. (1996). Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a highly immunogenic neuroblastoma onto a highly immunogenic one. Hum. Gene Ther. 7, 2059-2069.
26. ICHIKAWA, Y. (1996). Differentiation of a cell line of myeloid leukemia. J. Cell Physiol. 74, 223-234.
27. JACOBSON, S., SEKALY, R.P., JACOBSON, C.L., McFARLAND, H.F., and LONG, E.O. (1989). HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J. Virol. 63, 1756-1762.
28. JARAQUEMADA, D., MARTI, M., and LONG, E.O. (1990). An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J. Exp. Med. 172, 947-954.
29. LENSCHOW, D.J., ZENG, Y., THISTLETHWAITE, J.R., MONTAG, A., BRADY, W., GIBSON, M.G., LINSLEY, P.S., and BLUESTONE, J.A. (1992). Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789-792.
30. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153, 421-428.
31. LINSLEY, P.S., WALLACE, P.M., JOHNSON, J., GIBSON, M.G., GREENE, J.L., LEDBETTER, J.A., SINGH, C., and TEPPER, M.A. (1992). Immunosupression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792-795.
32. LIU, Y., JONES, B., ARUFFO, A., SULLIVAN, K.M., LINSLEY, P.S., and JANEWAY, C.J. (1992). Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J. Exp. Med. 175, 437-445.
33. MATULONIS, U.A., DOSIOU, C., LAMONT, C., FREEMAN, G.J., MAUCH, P., NADLER, L.M., and GRIFFIN, J.D. (1995). Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85, 2507-2515.
34. MULLER, A.J., YOUNG, J.C., PENDERGAST, A.M., PONDEL, M., LANDAU, N.R., LITTMAN, D.R., and WITTE, O.N. (1991). BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11, 1785-1792.
35. NUCHTERN, J.G., BIDDISON, W.E., and KLAUSNER, R.D. (1990). Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343, 74-76.
36. OSTRAND-ROSENBERG, S., THAKUR, A., and CLEMENTS, V. (1990). Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144, 4068-4071.
37. OSTRAND-ROSENBERG, S., ROBY, C.A., and CLEMENTS, V.K. (1991). Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 147, 2419-2422.
38. RESTIFO, N.P., ESQUIVEL, F., ASHER, A.L., STOTTER, H., BARTH, R.J., BENNINK, J.R., MULE, J.J., YEWDELL, J.W., and ROSENBERG, S.A. (1991). Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an antitumor immune response. J. Immunol. 147, 1453-1459.
39. RESTIFO, N.P., ESQUIVEL, F., KAWAKAMI, Y., YEWDELL, J.W., MULE, J.J., ROSENBERG, S.A., and BENNINK, J.R. (1993). Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272.
40. THOMPSON, C.B. (1995). Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81, 979-982.
41. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
42. TROJAN, J., JOHNSON, T.R., RUDIN, S.D., ILAN, J., TYKOCINSKI, M.L., and ILAN, J. (1993). Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259, 94-97.
43. VAN DER BRUGGEN, P., TRAVERSARI, C., CHOMEZ, P., LURQUIN, C., DEPLAEN, E., VAN DEN EYNDE, B., KNUTH, A., and BOON, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-647.
44. VAN SEVENTER, G.A., NEWMAN, W., SHIMIZU, Y., NUTMAN, T.B., TANAKA, Y., HORGAN, K.J., GOPAL, T.V., ENNIS, E., O'SULLIVAN, D., GREY, H., and SHAW, S. (1991). Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J. Exp. Med. 174, 901-913.
45. WALLICH, R., BULBUC, N., HAMMERLING, G.J., KATZAV, S., SEGAL, S., and FELDMAN, M. (1985). Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315, 301-305.
46. YANG, G., HELLSTRÖM, K.E., HELLSTRÖM, I., and CHEN, L. (1995). Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
47. YOKOCHI, T., HOLLY, R.D., and CLARK, E.A. (1982). B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J. Immunol. 128, 823-827.